NO2792369T3 - - Google Patents
Info
- Publication number
- NO2792369T3 NO2792369T3 NO14177306A NO14177306A NO2792369T3 NO 2792369 T3 NO2792369 T3 NO 2792369T3 NO 14177306 A NO14177306 A NO 14177306A NO 14177306 A NO14177306 A NO 14177306A NO 2792369 T3 NO2792369 T3 NO 2792369T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20854109P | 2009-02-25 | 2009-02-25 | |
| US26994409P | 2009-07-01 | 2009-07-01 | |
| US27136409P | 2009-07-20 | 2009-07-20 | |
| US27929309P | 2009-10-19 | 2009-10-19 | |
| EP10745872.1A EP2400987B1 (en) | 2009-02-25 | 2010-02-24 | Bendamustine cyclopolysaccharide compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2792369T3 true NO2792369T3 (OSRAM) | 2018-09-15 |
Family
ID=42631521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO14177306A NO2792369T3 (OSRAM) | 2009-02-25 | 2010-02-24 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8436032B2 (OSRAM) |
| EP (2) | EP2792369B1 (OSRAM) |
| JP (1) | JP5654498B2 (OSRAM) |
| KR (1) | KR101798951B1 (OSRAM) |
| CN (2) | CN102935080A (OSRAM) |
| AU (1) | AU2010217297A1 (OSRAM) |
| CA (1) | CA2753641C (OSRAM) |
| ES (2) | ES2525257T3 (OSRAM) |
| HU (1) | HUE038234T2 (OSRAM) |
| NO (1) | NO2792369T3 (OSRAM) |
| RU (2) | RU2734236C2 (OSRAM) |
| WO (1) | WO2010097700A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010217297A1 (en) | 2009-02-25 | 2011-10-20 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| RS62327B1 (sr) | 2010-01-28 | 2021-10-29 | Eagle Pharmaceuticals Inc | Formulacije bendamustina |
| WO2011103150A2 (en) * | 2010-02-18 | 2011-08-25 | Cephalon, Inc. | Lyophilized preparations of bendamustine |
| US20110207764A1 (en) * | 2010-02-23 | 2011-08-25 | Valery Alakhov | Cyclopolysaccharide compositions |
| US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| JP2014526512A (ja) * | 2011-09-18 | 2014-10-06 | ユーロ−セルティーク エス．エイ． | 医薬組成物 |
| TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| HRP20230276T1 (hr) | 2012-03-20 | 2023-04-28 | Eagle Pharmaceuticals, Inc. | Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni |
| DK2827862T3 (da) | 2012-03-20 | 2024-02-12 | Eagle Pharmaceuticals Inc | Formuleringer af bendamustin |
| US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| EP2925327B1 (en) * | 2012-11-30 | 2024-01-10 | The Regents of The University of California | Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression |
| WO2015031198A2 (en) * | 2013-08-27 | 2015-03-05 | Voudouris Vasilios | Bendamustine pharmaceutical compositions |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| US11266631B2 (en) | 2016-10-11 | 2022-03-08 | Purdue Pharmaceutical Products L.P. | Hodgkin lymphoma therapy |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| EP3691637A1 (en) * | 2017-10-05 | 2020-08-12 | TUBE Pharmaceuticals GmbH | Oral bendamustine formulations |
| US11730815B2 (en) * | 2018-11-26 | 2023-08-22 | Good Health, Llc | Stable liquid pharmaceutical compositions comprising bendamustine |
| WO2020128912A1 (en) | 2018-12-18 | 2020-06-25 | Mundipharma International Corporation Limited | Compounds for treating lymphoma or a t-cell malignant disease |
| US20220304983A1 (en) * | 2020-04-09 | 2022-09-29 | Bika Biotech (Guangzhou) Co., Ltd | Bendamustine composition and use thereof |
| CN111557904A (zh) * | 2020-04-09 | 2020-08-21 | 比卡生物科技（广州）有限公司 | 苯达莫司汀组合物及其用途 |
| US20240148696A1 (en) | 2022-10-25 | 2024-05-09 | Softkemo Pharma Inc. | Lyophilized bendamustine-cyclodextrin composition |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD159289A1 (de) | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
| US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US5068226A (en) * | 1987-12-07 | 1991-11-26 | Cyclex, Inc. | Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies |
| US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| DE59607089D1 (de) * | 1995-03-10 | 2001-07-19 | Roche Diagnostics Gmbh | Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung |
| JP4979843B2 (ja) * | 1995-03-10 | 2012-07-18 | ロッシュ ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 微粒子の形のポリペプチド含有投薬形 |
| US6624141B1 (en) * | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
| DE10204792A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Immuncytokine |
| EP1499361B1 (en) * | 2002-04-19 | 2012-08-08 | Novartis AG | Novel biomaterials, their preparation and use |
| SG176314A1 (en) * | 2002-12-31 | 2011-12-29 | Altus Pharmaceuticals Inc | Human growth hormone crystals and methods for preparing them |
| KR20070007075A (ko) * | 2003-12-31 | 2007-01-12 | 사이덱스 인크 | 술포알킬 에테르 시클로덱스트린 및 코르티코스테로이드를함유한 흡입용 제형 |
| EP1740184A1 (en) * | 2004-03-30 | 2007-01-10 | Pfizer Products Incorporated | Combinations of signal transduction inhibitors |
| JP2008501720A (ja) * | 2004-06-07 | 2008-01-24 | ナステック ファーマスーティカル カンパニー インク． | タンパク質又はポリペプチドである安定化剤不含インターフェロンベータの鼻腔内製剤 |
| WO2006013084A1 (en) * | 2004-08-03 | 2006-02-09 | Royal College Of Surgeons In Ireland | Phenytoin formulations, and uses thereof in wound healing |
| JP2008519032A (ja) * | 2004-11-03 | 2008-06-05 | キュラジェン コーポレイション | Ｆｇｆ−２０の調合物、生成方法および使用 |
| AU2005317047A1 (en) * | 2004-11-05 | 2006-06-22 | Cephalon, Inc. | Cancer treatments |
| US20060128653A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
| UA94036C2 (ru) * | 2005-01-14 | 2011-04-11 | Сефалон, Инк. | Фармацевтическая композиция бендамустина, предназначенная для лиофилизации |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| EP1848813B1 (en) | 2005-01-28 | 2013-04-10 | Brigham Young University | Bacterial glycolipid activation of cd1d-restricted nkt cells |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CN1846685A (zh) | 2006-01-25 | 2006-10-18 | 济南帅华医药科技有限公司 | 含苯达莫司汀和其增效剂的缓释注射剂 |
| US20100143481A1 (en) | 2006-11-08 | 2010-06-10 | Dinesh Shenoy | Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions |
| US8425459B2 (en) * | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| ES2373867T3 (es) | 2007-03-02 | 2012-02-09 | The University Of Wollongong | Composiciones y procedimientos para el suministro de agentes anticancerosos. |
| CN101219113A (zh) | 2008-01-28 | 2008-07-16 | 济南帅华医药科技有限公司 | 含苯达莫司汀的复方抗癌缓释注射剂 |
| AU2010217297A1 (en) | 2009-02-25 | 2011-10-20 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| CN101606934B (zh) | 2009-07-27 | 2011-09-28 | 江苏奥赛康药业有限公司 | 盐酸苯达莫司汀组合物 |
-
2010
- 2010-02-24 AU AU2010217297A patent/AU2010217297A1/en not_active Abandoned
- 2010-02-24 NO NO14177306A patent/NO2792369T3/no unknown
- 2010-02-24 JP JP2011550669A patent/JP5654498B2/ja active Active
- 2010-02-24 WO PCT/IB2010/000502 patent/WO2010097700A1/en not_active Ceased
- 2010-02-24 EP EP14177306.9A patent/EP2792369B1/en active Active
- 2010-02-24 CN CN2012104076231A patent/CN102935080A/zh active Pending
- 2010-02-24 HU HUE14177306A patent/HUE038234T2/hu unknown
- 2010-02-24 US US12/711,979 patent/US8436032B2/en active Active
- 2010-02-24 RU RU2016124871A patent/RU2734236C2/ru not_active Application Discontinuation
- 2010-02-24 ES ES10745872.1T patent/ES2525257T3/es active Active
- 2010-02-24 CN CN2010800183017A patent/CN102421451B/zh active Active
- 2010-02-24 ES ES14177306.9T patent/ES2675620T3/es active Active
- 2010-02-24 CA CA2753641A patent/CA2753641C/en active Active
- 2010-02-24 RU RU2011138844/15A patent/RU2591804C2/ru not_active Application Discontinuation
- 2010-02-24 EP EP10745872.1A patent/EP2400987B1/en active Active
- 2010-02-24 KR KR1020117022330A patent/KR101798951B1/ko active Active
-
2013
- 2013-03-11 US US13/793,442 patent/US8703964B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2525257T3 (es) | 2014-12-19 |
| CA2753641A1 (en) | 2010-09-02 |
| EP2792369B1 (en) | 2018-04-18 |
| US20130190372A1 (en) | 2013-07-25 |
| CN102421451B (zh) | 2013-11-06 |
| CN102935080A (zh) | 2013-02-20 |
| AU2010217297A1 (en) | 2011-10-20 |
| US8436032B2 (en) | 2013-05-07 |
| RU2016124871A (ru) | 2018-12-04 |
| RU2734236C2 (ru) | 2020-10-13 |
| EP2400987A1 (en) | 2012-01-04 |
| KR101798951B1 (ko) | 2017-11-20 |
| EP2792369A1 (en) | 2014-10-22 |
| US8703964B2 (en) | 2014-04-22 |
| CA2753641C (en) | 2014-09-16 |
| EP2400987B1 (en) | 2014-09-03 |
| RU2591804C2 (ru) | 2016-07-20 |
| HUE038234T2 (hu) | 2018-10-29 |
| JP5654498B2 (ja) | 2015-01-14 |
| EP2400987A4 (en) | 2012-08-22 |
| WO2010097700A1 (en) | 2010-09-02 |
| US20100216858A1 (en) | 2010-08-26 |
| RU2011138844A (ru) | 2013-04-10 |
| CN102421451A (zh) | 2012-04-18 |
| KR20120015294A (ko) | 2012-02-21 |
| JP2012519657A (ja) | 2012-08-30 |
| RU2016124871A3 (OSRAM) | 2019-11-11 |
| ES2675620T3 (es) | 2018-07-11 |